The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index; 93 of the 166 sources its claims cite were checked for support.
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Open accessAbstract
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.
Overview
CoChat Summary
TL;DR
This review argues that GLP-1-based therapies have antiinflammatory effects beyond their metabolic benefits, with evidence from preclinical and clinical studies across many organ systems. It also highlights that both direct immune-cell actions and indirect neural/metabolic mechanisms likely contribute, but the relative importance of each remains uncertain.
Key findings
- GLP-1 medicines lower inflammatory biomarkers in people with T2D and/or obesity, including plasma CRP; in semaglutide SUSTAIN and PIONEER trials, glucose and weight explained only 20%–60% of the observed CRP reductions.
- In preclinical models, acute GLP-1R agonism reduces inflammation independent of major weight loss, for example exenatide or semaglutide reduced circulating TNF-α in LPS-challenged mice, and exenatide downregulated TNF and IL1B in human PBMCs.
- The review highlights organ-specific antiinflammatory signals: in osteoarthritis, semaglutide improved WOMAC score by –41.7 points versus –27.5 with placebo in STEP-9; in MASH, semaglutide resolved steatohepatitis without worsening fibrosis in 63% versus 34% with placebo, and improved fibrosis without worsening steatohepatitis in 37% versus 23%.
- Clinical kidney data also support antiinflammatory/anti-fibrotic benefit: in FLOW, once-weekly 1 mg semaglutide reduced the primary composite risk by 24% and delayed CKD progression over 4 years.
Methods
- Narrative review synthesizing preclinical and clinical evidence on GLP-1 medicines and inflammation across intestinal, cardiovascular, liver, kidney, pulmonary, arthritis, and neuroinflammatory contexts.
- Draws on mouse models, human cell experiments, knockout/lineage-tracing studies, and randomized clinical trials and post hoc analyses; no new primary dataset is reported in the text provided.
- Main analytic approach is comparative interpretation of direct versus indirect antiinflammatory mechanisms, including weight loss–dependent and weight loss–independent effects.
Limitations
- The paper states that distinguishing metabolic from non-metabolic antiinflammatory effects will require complementary transgenic models, pair-feeding experiments, and interdisciplinary techniques; this indicates that current evidence is not sufficient to isolate mechanisms.
- Several mechanistic claims are explicitly uncertain, including the role of specific GLP-1R-expressing cells in heart, lung, liver, kidney, and brain, and whether neural mechanisms explain human biomarker changes.
- Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of prior studies rather than a single controlled experiment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
78 Valid · 3 Not valid · 49 Not checked · 22 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Both mouse and human endocardial endothelial cells express Glp1r/GLP1R (57).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1 medicines in cardiovascular inflammation
What the sources say
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Results report Glp1r expression in mouse endocardial endothelial cells, but say human endocardial endothelial cells did not co-localize with GLP1R expression. The Discussion describes this as a species-specific difference. The Conclusions and limitations caution that human endocardial cells were underrepresented in the datasets, limiting detection; the paper therefore does not establish their expression of GLP1R. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Administration of LPS, an endotoxin derived from Gram-negative bacteria that activates innate immunity and increases proinflammatory cytokines such as TNF-α, IL-6, and IL-1β, elevates circulating GLP-1 within 3 hours in mice and humans (5–7).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [6] source
Figure 2 (p. 5) reports plasma GLP-1 measurements 3 hours after LPS injection in mice, and the results (p. 4) state that LPS induced circulating GLP-1. The human results (p. 6) report increased plasma GLP-1 3 hours after LPS injection, compared with saline. (LLM, conf=0.93)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Results section reports increased plasma GLP-1 in mice after LPS injection, with measurements at 3 hours (Figure 3). It also says prior evidence links LPS administration to increased GLP-1 secretion in mice and humans, but our copy does not establish the 3-hour timing in humans. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both LPS- and IL-1β–induced GLP-1 release partly depends on IL-6 as shown in Il6–/– mice (5, 6), although the source of IL-6 that triggers L cells is unclear.”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
In “LPSs Induce GLP-1 Secretion through a TLR4Dependent Pathway” (p. 4), LPS caused an attenuated but detectable increase in GLP-1 secretion in Il6-deficient mice, supporting partial IL-6 dependence for the LPS response. The passages do not establish the same result for IL-1β-induced release in Il6-deficient mice. (LLM, conf=0.88)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, LPS infusion raises GLP-1 levels in healthy young subjects (9).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Partly supportedcites [9] sourceExperimental — accuracy not yet measured
The Conclusion reports elevated GLP-1 after dual LPS exposure, and the Discussion identifies the participants as healthy young men. The claim omits the prolonged, dual-exposure condition: the Discussion also notes that GLP-1 decreased during the first six hours of LPS exposure in a separate study of healthy young men. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For example, a single dose of exenatide or semaglutide reduced circulating TNF-α levels in mice challenged with LPS (21, 22).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > Weight loss–independent antiinflammatory effects of GLP-1 medicines
What the sources say
- Supportedcites [21] source
The Methods describe a single subcutaneous dose of semaglutide before an LPS challenge in mice. The Results report that semaglutide reduced plasma TNF-α at both 1 and 4 hours. This source supports the semaglutide part of the jointly cited sentence; it does not test exenatide. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [22] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 43 with their cited sources checked
Create a free account to see all 152 claims and every source verdict.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti‐inflammatory cytokines such as IL‐4 and IL‐10, together with additional metabolic mediators and adipokines including ghrelin, may provide complementary insight into the counter‐regulatory and immunometabolic effects of incretin‐based therapies in T2DM [65]”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [65]
Experimental — accuracy not yet measured
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 2×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements and direct antiinflammatory actions on the intestine.”
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789 · cited 1×
“Neuroinflammation is a hallmark of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases (45).”
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“Whether the renal arterial GLP-1R mediates the antiinflammatory actions of GLP-1 medicines in the kidney remains to be determined.”
Cited by
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 34
“These are likely mediated in large part by the pleiotropic antiinflammatory effects of GLP-1RAs (147).”
Voros, C., Chatzinikolaou, F. G., Papapanagiotou, I., Polykalas, S., Mavrogianni, D., Koulakmanidis, A.-M., Athanasiou, D., Kanaka, V., Bananis, K., Athanasiou, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020759 · Cited by 33
“Activation of GLP-1R in adipocytes inhibits the activity of pro-inflammatory cytokines such as TNF-α and IL-6, while initiating lipolysis, browning, and the secretion of adiponectin [6].”
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
GEORGAKOPOULOU, V. E., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100449 · Cited by 10
“Importantly, several of these effects have been observed in experimental settings that minimize or exclude weight change, supporting the existence of weight-independent pulmonary mechanisms [29].”
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 15
Metadata
- Authors
- Wong, C. K., & Drucker, D. J.
- Affiliations
- Lunenfeld-Tanenbaum Research Institute (CA)
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-11-03
- Volume
- 135
- Issue
- 21
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12578379
- OpenAlex
- W4415855223
- Semantic Scholar
- 4076facbe68bf6ad70262f15cb231a58eed3a21f
- Cited by
- 112
- References
- 92
- Citations by year
- 2026: 111 · 2025: 1
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Diabetes Canada
- Novo Nordisk (154321)
- Canadian Institutes of Health Research (15432_1, 19204)
- Banting and Best Diabetes Centre, University of Toronto (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, GLP-1 receptor signaling, anti-inflammatory activity, inflammation, type 2 diabetes, obesity, cardiovascular disease, chronic kidney disease, metabolic liver disease, arthritis, substance use disorders, neurodegenerative diseases, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Obesity, Signal Transduction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. https://app.cochat.ai/papers/10.1172/jci194751
- The paper
- Wong, C. K., & Drucker, D. J. (2025). Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. Journal of Clinical Investigation. https://doi.org/10.1172/jci194751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.